Vericel Corporation (VCEL)
- Previous Close
48.53 - Open
49.32 - Bid 48.79 x 200
- Ask 49.63 x 200
- Day's Range
49.19 - 49.71 - 52 Week Range
30.18 - 53.05 - Volume
8,659 - Avg. Volume
432,490 - Market Cap (intraday)
2.391B - Beta (5Y Monthly) 1.75
- PE Ratio (TTM)
4,919.50 - EPS (TTM)
0.01 - Earnings Date Jul 31, 2024 - Aug 5, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
55.50
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
vcel.comRecent News: VCEL
Performance Overview: VCEL
Trailing total returns as of 5/15/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VCEL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VCEL
Valuation Measures
Market Cap
2.36B
Enterprise Value
2.34B
Trailing P/E
4.85k
Forward P/E
270.27
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
11.16
Price/Book (mrq)
10.08
Enterprise Value/Revenue
11.26
Enterprise Value/EBITDA
347.98
Financial Highlights
Profitability and Income Statement
Profit Margin
0.22%
Return on Assets (ttm)
-0.75%
Return on Equity (ttm)
0.21%
Revenue (ttm)
207.78M
Net Income Avi to Common (ttm)
451k
Diluted EPS (ttm)
0.01
Balance Sheet and Cash Flow
Total Cash (mrq)
110.65M
Total Debt/Equity (mrq)
39.40%
Levered Free Cash Flow (ttm)
-4.63M
Research Analysis: VCEL
Company Insights: VCEL
VCEL does not have Company Insights